Abbott Labs profit tops forecasts on greater Humira sales, raises 2009 profit viewOctober 14th, 2009 Humira and nutrition sales lift Abbott 3Q profitNORTH CHICAGO, Ill. — Abbott Laboratories said Wednesday it beat its own expectations for the third quarter as sales of its drug Humira continued to climb, along with sales of medical products and nutritional formula for children.
Johnson & Johnson, Xerox, Abbott Labs, Applied Materials are among big market movers MondaySeptember 30th, 2009 Johnson & Johnson, Xerox, Abbott Labs big moversNEW YORK — The following stocks were among those that moved substantially or traded heavily Monday on the New York Stock Exchange:
NYSE:
Johnson & Johnson, up 65 cents at $61.27
The health care giant is jumping into the vaccine business by taking an 18 percent stake in Dutch biotechnology company Crucell NV. Accenture Ltd., up $1.77 at $37.89
A Wall Street analyst upgraded the consulting and outsourcing company to "Buy" and predicted improvement in its margins.
Abbott Labs buying Solvay's drug business for $6.6B bln in an overseas deal to boost portfolioSeptember 30th, 2009 Abbott buys Solvay pharma operations for $6.6BNEW YORK — Abbott Laboratories is buying the pharmaceutical business of Belgian chemicals maker Solvay for $6.6 billion in a move to further expand internationally and add to its product portfolio. North Chicago, Ill.-based Abbott already holds U.S.
Appeals court rules against military service members who sued over anthrax vaccine requirementSeptember 30th, 2009 Appeals court upholds dismissal of vaccine suitWASHINGTON — A federal appeals court has ruled that members of the military can be required to be vaccinated against anthrax. The U.S. Court of Appeals on Tuesday upheld a lower court's decision dismissing a case brought by eight service members who challenged the Food and Drug Administration's determination that the vaccine was effective.
Belgium's Solvay sells its pharmaceutical business to Abbott Laboratories of US for $7.6 blnSeptember 30th, 2009 Solvay sells pharma division to Abbott for $7.6BBRUSSELS — Solvay, the Belgian chemical and pharmaceutical group, said Monday it has agreed to sell its entire pharmaceutical business to Abbott Laboratories of Abbott Park, Illinois, for euro5.2 billion ($7.6 billion). The American company already holds U.S.
EU warns drug makers to look out for new antitrust investigationsSeptember 30th, 2009 EU warns of new antitrust probes for drug makersBRUSSELS — The European Union's top antitrust official warned drug makers Tuesday to "look out" for new investigations in coming months. EU Competition Commissioner Neelie Kroes said regulators were capitalizing on a recent broad inquiry into the pharmaceutical sector that aimed to find out why generic versions of branded drugs were slow to come to the market and if innovation is held back.
Federal judge orders MLB drug evidence preserved until gov't decides on Supreme Court appealSeptember 2nd, 2009 Federal judge orders MLB drug evidence preservedSAN FRANCISCO — A federal appellate judge has ordered the preservation of all evidence that allegedly shows 104 Major League Baseball players tested positive for steroids in 2003. The 9th U.S.
Federal appeals court revives whistle-blower suit alleging J&J illegally marketed anemia drugAugust 13th, 2009 Federal court OKs suit alleging illegal J&J salesBOSTON — A federal appeals court has revived a multibillion-dollar Medicare fraud case brought by whistle-blowers alleging Johnson & Johnson paid doctors kickbacks to wrongly prescribe an expensive drug. Two former salespeople for the health care giant allege J&J illegally marketed its blockbuster anemia drug Procrit.
Abbott Laboratories' 2nd-quarter profit falls on charges but lead drug regains sales momentumJuly 15th, 2009 Abbott profit dips on charges, generic competitionDrug developer and medical device maker Abbott Laboratories said Wednesday its second-quarter profit fell 3 percent on a mix of buyout charges and lower drug sales, but the results still met Wall Street forecasts. Pharmaceutical sales fell 4.3 percent as the company's anti-seizure drug Depakote lost market share to generic competition.
Abbott Laboratories' 2nd-quarter profit falls 3 percent on mix of charges but meets forecastsJuly 15th, 2009 Abbott Laboratories 2Q profit falls 3 percentNORTH CHICAGO, Ill. — Drug developer and medical device maker Abbott Laboratories said Wednesday its second-quarter profit fell 3 percent on a mix of buyout and restructuring charges, but the results still met Wall Street forecasts.
EU warns of antitrust probes into major drug makers for stalling cheaper generic versionsJuly 8th, 2009 EU warns of antitrust probes into drug makersBRUSSELS — The European Union is warning of a wave of antitrust probes into major drug makers Wednesday, saying they were deliberately stalling cheaper generic medicines. It started an investigation Wednesday into France's Les Laboratoires Servier for hindering the launch of generic versions of its heart disease drug.
Federal appeals court upholds prison term for drug smuggler shot by border agentsJune 30th, 2009 Prison terms upheld for smuggler shot at borderEL PASO, Texas — A federal appeals court has upheld the prison term for an admitted drug smuggler wounded in a controversial shooting by Border Patrol agents. The 5th U.S.
Supreme Court steps into international child custody disputeJune 29th, 2009 Court takes on international child custody caseWASHINGTON — The Supreme Court agreed Monday to hear arguments in a child custody dispute between a Texas mother and a British father that tests the boundaries of an international treaty. The court will take its first look at how American authorities handle the Hague Convention on child abduction, aimed at preventing one parent from taking children to other countries without the other's permission.
NFL goes to Supreme Court for bigger legal victory in antitrust case involving merchandiseJune 27th, 2009 NFL asks for court ruling on merchandise caseWASHINGTON — In the legal equivalent of running up the score, the National Football League is going to the Supreme Court in search of a bigger victory in an antitrust tussle over team merchandise than it already won from a lower court. The Supreme Court could decide as early as Monday whether it will hear the case, which involves American Needle Inc.'s challenge to the league's exclusive contract for selling headwear such as caps and hats with team logos on them.
NFL wants court to grant it wider latitude in antitrust matters concerning league merchandiseJune 27th, 2009 NFL asks Supreme Court to grant it wider latitudeWASHINGTON — In the legal equivalent of running up the score, the National Football League is going to the Supreme Court in search of a bigger victory in an antitrust tussle over team merchandise than it already won from a lower court. The Supreme Court could decide as early as Monday whether it will hear the case, which involves American Needle Inc.'s challenge to the league's exclusive contract for selling headwear such as caps and hats with team logos on them.